Stock CONTEXT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Market Closed - Nasdaq
Other stock markets
 01:30:00 17/07/2024 am IST 		5-day change 1st Jan Change
2.19 USD -0.45% Intraday chart for Context Therapeutics Inc. +19.57% +94.69%
08/05 Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
06/05 Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
AQ
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC
CI
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76
CI
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC
CI
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
CI
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc
CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
AQ
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Context Therapeutics to Participate in Two August 2023 Investor Conferences
AQ
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update
AQ
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
AQ
CONTEXT THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Testicular Cancer Pipeline Assessment, FDA Approvals, Clinical Trials, Emerging Drugs, and Therapeutics Assessment 2023 | Major Companies - Sanofi, Seagen Inc., BioNTech, Seagen, and Others
AQ
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting
AQ
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
CONTEXT THERAPEUTICS INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Context Therapeutics Inc.